Advertisement

Muskelrelaxantien 1997 — Ein Update

  • R. Hofmockel
  • G. Benad
Conference paper
Part of the Refresher Course Aktuelles Wissen für Anästhesisten book series (REFRESHER COUR, volume 23)

Zusammenfassung

Innerhalb der letzten 15 Jahre konnten auf dem Gebiet der Forschung, Entwicklung, des klinischen Einsatzes und der Überwachung von Muskelrelaxantien beachtliche Fortschritte erzielt und damit ein weiterer Beitrag zur Erhöhung der intra- und postoperativen Sicherheit der Patienten geschaffen werden. Diese Entwicklung begann, nachdem sich in den 8oer Jahren die neuen, mittellang wirkenden Nichtdepolarisationsblocker Vecuronium und Atracurium, aber auch das langwirkende Pipecuronium fest im klinischen Alltag etablieren konnten und erreichte durch die klinische Einführung der Benzylisoquinolindiester Mivacurium und Cisatracurium und des Steroidrelaxans Rocuronium einen vorläufigen Höhepunkt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abouleish E, Abboud T, Lechevalier T, Zhu J, Chalian A, Alford K (1994) Rocuronium (Org 9426) for Caesarean section. Br J Anaesth 73: 336–341.PubMedCrossRefGoogle Scholar
  2. 2.
    Agoston S (1995) Onset time and evaluation of intubating conditions: Rocuronium in perspective. Eur J Anaesthesiol; 12: 31–37.Google Scholar
  3. 3.
    Bartkowski RR, Witkowski TA, Azad S, Lessin J, Marr A (1993) Rocuronium onset of action: a comparison with atracurium and vecuronium. Anesth Analg 77: 574–578.PubMedCrossRefGoogle Scholar
  4. 4.
    Booij LH, Knape HT (1991) The neuromuscular blocking effect of ORG 9426. A new intermediately-acting steroidal non-depolarizing relaxant in man. Anaesthesia 46: 341–343.Google Scholar
  5. 5.
    Bowman WC, Rodger IW, Houston J, Marshall RJ, Mclndewar I. Structure (1988) Action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anaesthetized cat. Anesthesiology 69: 57–62.Google Scholar
  6. 6.
    Brandom BW, Sarner JB, Woelfel SK, Dong ML, Horn MC, Borland LM, Cook DR, Foster VJ, BF McNulty, Weakly JN (1990) Mivacurium infusion requirements in pediatric surgical patients during nitrous oxide-halothane and during nitrous oxide-narcotic anesthesia. Anesth Analg 71: 16–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Cook DR (1993) Mivacurium in infants and children. J Drug Dev 5: (Suppl 1) 7–14.Google Scholar
  8. 8.
    Cook DR, Freeman JA, Lai AA, Kang Y, Stiller RL, Aggarwal S, Harrelson JC, Welch RM, Samara B (1992) Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 69: 580–585.PubMedCrossRefGoogle Scholar
  9. 9.
    Cooper RA, Mirakhur RK, Clarke RS, Boules Z (1992) Comparison of intubating conditions after administration of ORG 9246 (rocuronium) and suxamethonium. Br J Anaesth 70: 269–273.CrossRefGoogle Scholar
  10. 10.
    Deriaz H, Schmautz E, Vrilon M, Flienhart A (1994) Pharmacodynamics of repeated doses of 51W89 during surgery. Anesthesiology 81: A1092.CrossRefGoogle Scholar
  11. 11.
    Engbaek J, Ostergaard D, Viby-Mogensen J (1989) Double burst stimulation ( DBS) A new pattern of nerve stimulation to identify residual neuromuscular block. Br J Anaesth 62: 274–278.Google Scholar
  12. 12.
    Foldes FF, Nagashima H, Nguyen HD, Schiller WS, Mason MM, Ohta Y (1991) The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia. Anesthesiology 75: 191–196.PubMedCrossRefGoogle Scholar
  13. 13.
    Frampton JE, McTavish D (1993) Mivacurium. A review of its pharmacology and therpeutic potential in general anaesthesia. Drugs 45: 1066–1089.Google Scholar
  14. 14.
    Goudsouzian NG, Alifimoff JK, Eberly C, Smeets R, Griswold J, Miler V, McNulty BF, Savarese J J (1989) Neuromuscular and cardiovascular effects of mivacurium in children. Anesthesiology. 70: 237–242.PubMedCrossRefGoogle Scholar
  15. 15.
    Hofmockel R, Benad G, Jantschulev S (1995) Vergleich der neuromuskulären Blockade von Mivacurium und Atracurium. Anaesthesiol Reanim 20: 4–11PubMedGoogle Scholar
  16. 16.
    Hofmockel R, Benad G, Kabott A (1994) Mechanomyographische und elektromyographische Untersuchungen zur endotrachealen Intubation mit zwei verschiedenen Rocuronium-Dosierungen. Anaesthesiol Reanim 19: 144–148.PubMedGoogle Scholar
  17. 17.
    Huizanga AC, Vandenbrom RH, Wierda JM, Hommes FD, Hennis PJ (1992) Intubating conditions and onset of neuromuscular block of rocuronium (ORG 9426); a comparison with suxamethonium. Acta Anaesthesiol. Scand. 36: 463–468.Google Scholar
  18. 18.
    Hunter JM, De Wolf A (1996) The pharmacodynamics and pharmacokinetics of cisatracurium in patients with renal or hepatic failure. Curr Opin Anaesthesiol 9: 42–46.CrossRefGoogle Scholar
  19. 19.
    Jones RM (1995) Mivacurium in special patient groups. Acta Anaesthesiol Scand 39: 47 - 54.CrossRefGoogle Scholar
  20. 20.
    Kaiser E, Petit D, Quinot JF, Suppini A, Sallaberry M (1995) Curarisation prolongee apres mivacurium par deficit en pseudocholinesterases plasmatiques. Ann Fr Anesth Reanim 14: 505–507PubMedCrossRefGoogle Scholar
  21. 21.
    Konstadt SN, Reich DL, Stanley TE, DePerio M, Chuey C, Schwartzbach C, Abou-Donia M (1995) A two-center comparison of the cardiovascular effects of cisatracurium ( NIMBEX) and vecuronium in patients with coronary artery disease. Anesth Analg; 81: 1010–1014.Google Scholar
  22. 22.
    Kopman AF (1989) Pancuronium, gallamine and d-Tubocurarine compared: Is speed of onset inversely related to drug potency? Anesthesiology; 70: 915–920.PubMedCrossRefGoogle Scholar
  23. 23.
    Lake CL (1993) American monitoring: Standards and state of the art. Infusther Transfusionsmed 20: 104–110.Google Scholar
  24. 24.
    Lambalk LM, De-Wit AP, Wierda JM, Hennis PJ, Agoston S (1991) Dose response relationship and time course of action of ORG 9426. A new muscle relaxant of intermediate duration evaluated under various anaesthetic techniques. Anaesthesia; 46: 907–911.Google Scholar
  25. 25.
    Lapeyre G, Dubois M, Lea D, Kataria E, Tran D (1990) Effects of 3 intubating doses of ORG 9426 in humans. Anesthesiology 73: 34–36CrossRefGoogle Scholar
  26. 26.
    Lien CA (1993) What is really new about the new relaxants? Anesthesiol Clin North Am 11: 729–778.Google Scholar
  27. 27.
    Littlejohn IH, Abhay K, El Sayad A, Broomhead CJ, Duvaldestin P, Flynn PJ (1995) Intubating conditions following 1R eis, l’R eis atracurium (51W89). Anaesthesia 50: 499–502.PubMedCrossRefGoogle Scholar
  28. 28.
    Meretoja OA, Taivainen T (1995) Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. Br J Anaesth 74: 6–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Meretoja OA; Taivainen T; Erkola O; Rautoma P; Juvakoski M (1995) Dose-response and time-course of effect of rocuronium bromide in paediatric patients. Eur J Anaesthesiol 12: 19–22.Google Scholar
  30. 30.
    Mogorian T, Flannery KB, Miller RD (1993) Comparison of rocuronium, succinylcholine, and vecuronium for rapid sequence induction of anaesthesia in adult patients. Anesthesiology 79: 913–918.CrossRefGoogle Scholar
  31. 31.
    Muchhai KK, Viby-Mogensen J, Fernando PUE (1987) Evaluation of intense neuromuscular blockade caused by vecuronium using posttetanic count ( PTC ). Anesthesiology. 66: 846–849.Google Scholar
  32. 32.
    Ostergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J (1993) Mivacurium-induced neuromuscular blockade in patients with atypical plasma Cholinesterase. Acta Anaesthesiol Scand 37: 314–318.PubMedCrossRefGoogle Scholar
  33. 33.
    Pavlin EG, Duvaldestin P, Belmont MR, Flynn PJ (1996) The use of cisatracurium for tracheal intubation. Curr Opin Anaesthesiol 9: 23–26Google Scholar
  34. 34.
    Puhringer FK, Khuenl-Brady, KS, Koller J, Mitterschiffthaler G (1992) Evaluation of the endotracheal intubation conditions of rocuronium (ORG 9426) and succinylcholine in outpatient surgery. Anesth. Analg. 76: 37–40.Google Scholar
  35. 35.
    Robertson EN, Hull JM, Verbeek AM, Booij LHD (1994) A comparison of rocuronium and vecuronium: The pharmacodynamic, cardiovascular and intra-ocular effects. Eur J Anaesthesiol 11: 116–121.Google Scholar
  36. 36.
    Savarese JJ (1993) Mivacurium: A comparison with other benzylisoquinolinium non-depolarising muscle relaxants. J Drug Dev 5: 1–5.Google Scholar
  37. 37.
    Savarese JJ, HH Ali, SJ Basta, PB Embree, RPF Scott, N Sunder, JN Weakly, WB Wastila, HA El-Sayad (1988) The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U) Anesthesiology 68: 723–732.PubMedGoogle Scholar
  38. 38.
    Scheiber G; Ribeiro FC; Marichal A; Bredendiek M; Renzing K (1996) Intubating conditions and onset of action after rocuronium, vecuronium, and atracurium in young children. Anesth Analg 83 320–324.PubMedGoogle Scholar
  39. 39.
    Schmith VD; Phillips L; Kisor DF; Fiedler Kelly J; Weatherley BC (1996) Pharmacokinetics/pharmacodynamics of cisatracurium in healthy adult patients. Curr Opin Anaesthesiol 9: 9–15Google Scholar
  40. 40.
    Viby Morgensen J, Engbaek J, Eriksson LI, Gramstad L, Jensen E, Jensen FS;, Koscielniak Nielsen Z, Skovgaard LT, Ostergaard D (1996) Good clinical research practice ( GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 40: 59–74.Google Scholar
  41. 41.
    Viby-Mogensen J, JensenE, WernerM, Kirkegaard-NielsenH (1988) Measurement of acceleration: A new method of monitoring neuromuscular function. Acta Anaesthesiol Scand 32: 45-48.Google Scholar
  42. 42.
    Wastila WB, Maehr RB, LaMunion GL, Belmont MR, Savarese JJ (1996) Preclinical pharmacology of cisatracurium besylate. Curr Opin Anaesthesiol 9: 2–8.Google Scholar
  43. 43.
    Wierda-JMKH; Proost-JH (1995) The pharmacokinetics and the pharmacokinetic-dynamic relationship of rocuronium bromide. Anaesth Pharmacol Rev. 3: 192–201.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • R. Hofmockel
  • G. Benad

There are no affiliations available

Personalised recommendations